Abstract
A Canadian-led phase 3 trial has shown that taking 8 mg of rosiglitazone (Avandia) daily, coupled with lifestyle counselling, can reduce the risk of developing Type 2 diabetes by 62% in individuals at high risk. The study results made headlines worldwide, but a drug expert argues that lifestyle
Published Version (
Free)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have